Dr. Ashley Froese on Retatrutide: Why It's the "King" of Fat Loss Peptides, Fact-Checked

The video description promotes her peptide course and includes paid affiliate links, including a body-composition device and BPC-157 products. Those commercial links do not establish the clinical claims discussed below.

The GLP-1 to GIP Progression: Tirzepatide's Advantage

"GIP receptors in the brain antagonize or dampen the nausea signals"

1:35

Dr. Froese explains that tirzepatide combines GLP-1 and GIP receptor agonism, and that GIP dampens the nausea triggered by GLP-1 alone:

"Research suggests that GIP receptors in the brain antagonize or dampen the nausea signals triggered by pure GLP-1 agonism. Essentially, Tirzepatide hits that stop eating button while simultaneously pushing a don't throw up button."

— Dr. Ashley Froese

Tirzepatide’s two receptor targets are established. Claims about which receptor does most of the work, or guarantees better tolerability, go beyond the clinical comparison.

GIP and Futile Calcium Cycling

"A futile calcium cycle — revving your engine while in neutral"

2:15

Dr. Froese describes a mechanism by which GIP increases energy expenditure:

"Hitting your GIP receptors using tirzepatide causes a transient increase in energy expenditure for no good reason at all. We call it a futile calcium cycle, meaning a calcium pump in your cells gets activated and starts moving calcium back and forth across the membranes for no functional reason other than just to consume energy. It's like revving your engine while you're in neutral."

— Dr. Ashley Froese

The calcium-cycling study is real, but the experimental system matters: adipose GIP receptor overexpression in mice is different from treating a person with tirzepatide. The video’s analogy explains a proposed mechanism; it does not establish the magnitude of a human metabolic effect.

Retatrutide's Glucagon Component: The Metabolic "Cheat Code"

"Glucagon does this through mitochondrial uncoupling"

3:25

Dr. Froese argues that retatrutide's glucagon receptor agonism provides a metabolic advantage through thermogenesis:

"Glucagon does this through a process called mitochondrial uncoupling, essentially leaking protons through the electron transport chain... instead of making ATP, you get energy released purely as heat. The body literally starts wasting calories as heat."

— Dr. Ashley Froese

The clinical trials measure the combined drug’s effects. Continued weight loss does not prove that mitochondrial uncoupling prevented metabolic adaptation, and preclinical thermogenesis findings do not establish an exercise-equivalent benefit.

Muscle Loss: "Up to 40% of Weight Lost Can Be Lean Mass"

"Up to 40% of weight lost can be lean mass"

5:05

Dr. Froese raises the muscle loss concern:

"What we've seen in the clinical trials so far is that up to 40% of weight lost on these GLP agonist peptide blends can be lean mass or muscle. 40%. That is 40% of your metabolic capacity."

— Dr. Ashley Froese

A percentage of weight lost is not a percentage of metabolic capacity. Lean mass includes non-muscle tissue, so neither a DXA ratio nor a cross-trial comparison supports that claim. The distinction matters when discussing strength, function and nutrition.

Heart Rate Increase: 5 to 10 BPM

"An increase of 5 to 10 beats per minute in resting heart rate"

6:55

"There's a natural pacemaker in your heart that has glucagon receptors on it. And so research is showing an increase of 5 to 10 beats per minute in resting heart rates."

— Dr. Ashley Froese

Phase 2 supports dose-dependent heart-rate increases, peaking at 24 weeks and subsequently declining. It does not establish a universal 5–10 BPM change or prove that glucagon receptors in the human sinoatrial node caused it.

Allodynia at High Doses

"About 20% reported allodynia where their skin felt sunburned"

7:20

"About 20% of the participants in the studies on high doses — meaning 12 milligrams of retatrutide — reported a side effect of allodynia where their skin felt like it had been sunburned."

— Dr. Ashley Froese

The 20.9% figure matches TRIUMPH-4’s dysesthesia category at 12 mg. It does not mean 20.9% specifically had allodynia, which describes pain from ordinarily non-painful stimuli. Dysesthesia also appears in current Wegovy and Zepbound labels, and its mechanism has not been established by this trial.

Pancreatitis Risk: "Less Than 0.5%"

"The risk for pancreatitis still exists but in the clinical trials the incidence was less than 0.5%."

— Dr. Ashley Froese

The previous assertion of no Phase 2 pancreatitis cases was incorrect. The study reported one acute pancreatitis event; longer and larger safety datasets are needed to estimate uncommon risks.

Dosing: The Trial Protocol

"The doses were 2 mg, 4 milligrams, 6, 9, and 12 milligrams spaced out in 4 week intervals."

— Dr. Ashley Froese

Her sequence is consistent with TRIUMPH-4. The earlier fact-check incorrectly substituted Phase 2 dose groups and an incorrect escalation schedule. Trial dosing is not an approved self-treatment protocol.

Microdosing and Receptor Desensitization

"You might actually accelerate tolerance"

9:00

"By microdosing and keeping those receptors under 24/7 high-level tension, you might actually accelerate tolerance, meaning you'd need higher and higher doses sooner to get the same effect."

— Dr. Ashley Froese

This is a theoretical claim she explicitly labels as such ("this is not fact, it's just a theory I have"). The underlying biology — that incretin receptors undergo desensitization and internalization when continuously stimulated — is well-established. Whether splitting a weekly dose into smaller daily doses meaningfully accelerates this process in practice is unknown. Her intellectual honesty in labeling this as speculation is appreciated.

Frequently Asked Questions

Sources

• FDA/Novo Nordisk. Current Wegovy label.
• FDA. Current Zepbound label.
• Lilly. TRIUMPH-4 results and 2026 filing update.
• Lancet Diabetes & Endocrinology. Retatrutide DXA substudy.
• Froese, A. (2026). "Dr. Explains Why Retatrutide is KING of Fat Loss Peptides." This Is Not Covered (YouTube). Watch on YouTube
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Yu, X., et al. (2025). The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure. Cell Metabolism, 37:187–204.e7. DOI: 10.1016/j.cmet.2024.11.003
• Douros, J.D. & Flak, J.N. (2025). GIP receptor agonism and GI tolerability of incretin-based therapies. Frontiers in Endocrinology. DOI: 10.3389/fendo.2025.1530985

• Eli Lilly (2025). TRIUMPH-4 Phase 3 results press release.

• SEMALEAN study (2025). Body composition outcomes with semaglutide 2.4mg. PMID: 41068996.